DR. BRUCE KENDRICK PATTERSON, MD
Medical Practice at Hillview Ave, Palo Alto, CA
License number
California G87068
Category
Medical Practice
Type
Clinical Pathology/Laboratory Medicine
Address
Address
3375 Hillview Ave, Palo Alto, CA 94304
Phone
(650) 725-3864
(650) 498-7241 (Fax)
(650) 498-7241 (Fax)
Professional information
Ceo At Incelldx
Position:
CEO at IncellDx
Location:
San Francisco Bay Area
Industry:
Medical Devices
Work:
IncellDx
since Oct 2009
-
CEO
Stanford University School of Medicine
- Palo Alto, CA Aug 2003 - Apr 2011
-
Associate Professor, Director Diagnostic Virology
Education:
University of Michigan 1981 - 1985
Bachelor of Science (BS), Molecular Biology/Microbiology Northwestern University - The Feinberg School of Medicine
Doctor of Medicine (MD), Virology
Bachelor of Science (BS), Molecular Biology/Microbiology Northwestern University - The Feinberg School of Medicine
Doctor of Medicine (MD), Virology
Dr. Bruce K Patterson, Palo Alto CA - MD (Doctor of Medicine)
Specialties:
Cytopathology
Address:
3375 Hillview Ave STE 2913, Palo Alto 94304
(650) 725-3864 (Phone), (650) 498-7241 (Fax)
(650) 725-3864 (Phone), (650) 498-7241 (Fax)
Languages:
English
Education:
Medical School
Northwestern Center Feinberg School of Medicine
Graduated: 1989
Northwestern Center Feinberg School of Medicine
Graduated: 1989
Bruce Kendrick Patterson, Palo Alto CA
Specialties:
Pathologist
Address:
3375 Hillview Ave, Palo Alto, CA 94304
Methods And Systems For Predicting Whether A Subject Has A Cervical Intraepithelial Neoplasia (Cin) Lesion From A Suspension Sample Of Cervical Cells
US Patent:
2012012, May 17, 2012
Filed:
Nov 10, 2011
Appl. No.:
13/294101
Inventors:
Bruce K. Patterson - Palo Alto CA, US
International Classification:
G01N 33/569, C12M 1/34
US Classification:
435 5, 4352872
Abstract:
Methods of predicting whether a subject has a cervical intraepithelial neoplasia (CIN) lesion are provided. Aspects of the methods include obtaining both morphometric and biomarker data from a liquid cervical cellular sample and then using both types of data to predict whether the subject has a CIN lesion. Also provided are systems that find use in practicing the methods. The methods and systems find use in a variety of applications, including cervical cancer screening applications.
Hpv E6, E7 Mrna Assay And Methods Of Use Thereof
US Patent:
7524631, Apr 28, 2009
Filed:
Feb 2, 2005
Appl. No.:
11/050384
Inventors:
Bruce K. Patterson - Palo Alto CA, US
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Provided is an HPV E6, E7 mRNA assay, referenced herein as the “In Cell HPV Assay,” that is capable of sensitive and specific detection of normal cervical cells undergoing malignant transformation as well as abnormal cervical cells with pre-malignant or malignant lesions. The In Cell HPV Assay identifies HPV E6, E7 mRNA via in situ hybridization with oligonucleotides specific for HPV E6, E7 mRNA and quantitates the HPV E6, E7 mRNA via flow cytometry. The In Cell HPV Assay can be carried out in less than three hours directly from liquid-based cervical (“LBC”) cytology specimens. The In Cell HPV Assay provides an efficient and highly sensitive alternative to the Pap smear for determining abnormal cervical cytology.
Hpv E6, E7 Mrna Assay And Methods Of Use Thereof
US Patent:
7888032, Feb 15, 2011
Filed:
Feb 24, 2009
Appl. No.:
12/391634
Inventors:
Bruce K. Patterson - Palo Alto CA, US
Assignee:
IncellDx, Inc. - Menlo Park CA
International Classification:
C12Q 1/68
US Classification:
435 6
Abstract:
Provided is an HPV E6, E7 mRNA assay, referenced herein as the “In Cell HPV Assay,” that is capable of sensitive and specific detection of normal cervical cells undergoing malignant transformation as well as abnormal cervical cells with pre-malignant or malignant lesions. The In Cell HPV Assay identifies HPV E6, E7 mRNA via in situ hybridization with oligonucleotides specific for HPV E6, E7 mRNA and quantitates the HPV E6, E7 mRNA via flow cytometry. The In Cell HPV Assay can be carried out in less than three hours directly from liquid-based cervical (“LBC”) cytology specimens. The In Cell HPV Assay provides an efficient and highly sensitive alternative to the Pap smear for determining abnormal cervical cytology.
Hpv E6, E7 Mrna Assay And Methods Of Use Thereof
US Patent:
2010012, May 13, 2010
Filed:
Dec 22, 2009
Appl. No.:
12/645202
Inventors:
Bruce K. Patterson - Palo Alto CA, US
International Classification:
C12Q 1/70
US Classification:
435 5
Abstract:
Provided is an HPV E6, E7 mRNA assay, referenced herein as the “In Cell HPV Assay,” that is capable of sensitive and specific detection of normal cervical cells undergoing malignant transformation as well as abnormal cervical cells with pre-malignant or malignant lesions. The In Cell HPV Assay identifies HPV E6, E7 mRNA via in situ hybridization with oligonucleotides specific for HPV E6, E7 mRNA and quantitates the HPV E6, E7 mRNA via flow cytometry. The In Cell HPV Assay can be carried out in less than three hours directly from liquid-based cervical (“LBC”) cytology specimens. The In Cell HPV Assay provides an efficient and highly sensitive alternative to the Pap smear for determining abnormal cervical cytology.
Patterns Of Known And Novel Small Rnas In Human Cervical Cancer
US Patent:
2010023, Sep 16, 2010
Filed:
Jun 30, 2009
Appl. No.:
12/459409
Inventors:
Weng Onn Lui - Stanford CA, US
Nader Pourmand - San Mateo CA, US
Bruce K. Patterson - Palo Alto CA, US
Andrew Fire - Stanford CA, US
Nader Pourmand - San Mateo CA, US
Bruce K. Patterson - Palo Alto CA, US
Andrew Fire - Stanford CA, US
International Classification:
A61K 31/713, C12Q 1/68, C40B 30/00, A61P 35/00
US Classification:
514 44 A, 435 6, 506 7
Abstract:
Small RNA sequences that are differentially expressed in SCCC cells are provided. The sequences find use in diagnosis of cancer, and classification of cancer cells according to expression profiles. The methods are useful for detecting cervical cancer cells, facilitating diagnosis of cervical cancer and the severity of the cancer (e.g., tumor grade, tumor burden, and the like) in a subject, facilitating a determination of the prognosis of a subject, and assessing the responsiveness of the subject to therapy.
Leukemia Inhibitory Factor (Lif) For Use In Repressing Human Papillomavirus (Hpv) Transcription
US Patent:
2012002, Jan 26, 2012
Filed:
Jun 23, 2011
Appl. No.:
13/167404
Inventors:
Joseph M. Bay - Palo Alto CA, US
Bruce K. Patterson - Palo Alto CA, US
Nelson Teng - Hillsborough CA, US
Bruce K. Patterson - Palo Alto CA, US
Nelson Teng - Hillsborough CA, US
Assignee:
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNVERSITY - PALO ALTO CA
International Classification:
A61K 38/19, A61P 15/00, A61P 35/00, A61P 31/20
US Classification:
424 851
Abstract:
Embodiments of the invention are related to leukemia inhibitory factor (LIF) for use in repressing human papillomavirus (HPV) transcription. Processes and related kits are described for treating a HPV-associated papillomatous proliferation, for treating a HPV-associated genital, anal, vulvar, penile, oral, or laryngeal wart, for treating HPV-associated cervical dysplasia or cervical cancer, and for repressing HPV transcription, by administering LIF to a patient in need thereof. A related embodiment is treatment of HPV-16 by use of LIF.